Once‑daily oral program advancing toward Phase 2 for UC and FSCD.
A selective JAK1/TYK2 inhibitor with gut-restricted exposure, designed for superior efficacy and safety in inflammatory bowel disease.
Moderate-to-severe UC patients unresponsive to conventional therapy. Aiming for mucosal healing and steroid-free remission.
Perianal and enterocutaneous fistulas. Targeting fistula closure and sustained clinical response.
DCGI & FDA submission completed.
First-in-human safety & PK in 48 volunteers.
Proof-of-concept in 30 patients.
Global multi-center trial initiation.